Conference themes The last 12 months have highlighted key milestones in European biopharma investment– from GSK injecting €1 million into a 15-building biotech campus in Stevenage, to AstraZeneca investing £1 billion into a new R AND D and Corporate HQ. As the pressure to expand and continue pipeline progression within a scattered and distributed market, there has never been a better time to know how to navigate unknown waters.
